Goldman initiated coverage on Legend Biotech with a new price target
$LEGN
Biotechnology: Pharmaceutical Preparations
Health Care
Goldman initiated coverage of Legend Biotech with a rating of Buy and set a new price target of $90.09
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/8/2024 | $86.00 | Buy | Redburn Atlantic |
| 6/17/2024 | $88.00 | Buy | Truist |
| 5/24/2024 | $86.00 → $73.00 | Buy | H.C. Wainwright |
| 5/23/2024 | $60.00 | Buy | Deutsche Bank |
| 4/17/2024 | $65.00 | Sector Perform → Sector Outperform | Scotiabank |
| 4/3/2024 | $82.00 | Overweight | Cantor Fitzgerald |
| 3/13/2024 | $86.00 | Outperform | Raymond James |
| 12/19/2023 | Sector Perform | Scotiabank |